Immunosuppressives in Uveitis and Ocular Inflammation

  • Pichaporn Artornsombudh
  • John H. Kempen


Inadequately controlled uveitis is a leading cause of permanent visual loss, accounting for 5–20 % of cases of legal blindness [1–4]. Ocular inflammation is the principal cause of complications and morbidities. Delayed or inadequate control of inflammation can lead to serious sequelae resulting in visual impairment [5–8]. Therefore, the primary goal of management is to control the inflammation. There are two phases of treatment of ocular inflammation. First is induction of control of inflammation, the goal of which is to suppress the sight-threatening ocular inflammation as soon as possible with a rapidly effective medication, usually using topical, systemic, and/or injected corticosteroids. For remitting forms of uveitis, this may be the only treatment necessary. For chronic disease requiring suppressive therapy, the second aim is maintenance of control of inflammation after successful treatment in order to prevent recurrence or relapse of the ocular inflammation. Immunosuppressives have their primary role in maintenance of control of inflammation.


Juvenile Idiopathic Arthritis Mycophenolate Mofetil Ocular Inflammation Relapse Polychondritis Intravenous Cyclophosphamide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Conflict of Interest


Financial Disclosures

The author(s) have made the following disclosure(s): John H. Kempen: (consultant) Abbvie; (consultant) Lux Biosciences; (consultant) Allergan; (consultant) Alcon; (consultant) Can-Fite; (consultant) Clearside; (consultant) Xoma.


  1. 1.
    Darrell RW, Wagener HP, Kurland LT. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol. 1962;68:502–14.PubMedGoogle Scholar
  2. 2.
    Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14(5–6):303–8.PubMedGoogle Scholar
  3. 3.
    Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–6.PubMedCentralPubMedGoogle Scholar
  4. 4.
    Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80(9):844–8.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Gregory 2nd AC, Kempen JH, Daniel E, et al. Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study. Ophthalmology. 2013;120(1):186–92.PubMedCentralPubMedGoogle Scholar
  6. 6.
    Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997;104(2):236–44.PubMedGoogle Scholar
  7. 7.
    Dana MR, Merayo-Lloves J, Schaumberg DA, Foster CS. Prognosticators for visual outcome in sarcoid uveitis. Ophthalmology. 1996;103(11):1846–53.PubMedGoogle Scholar
  8. 8.
    Thorne JE, Woreta F, Kedhar SR, et al. Juvenile idiopathic arthritis-associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007;143(5):840–6.PubMedGoogle Scholar
  9. 9.
    Gordon DM, McLean JM. Effects of pituitary adrenocorticotropic hormone (ACTH) therapy in ophthalmologic conditions. JAMA. 1950;142:1271–6.Google Scholar
  10. 10.
    Gordon DM, Mc LJ, Koteen H, et al. The use of ACTH and cortisone in ophthalmology. Am J Ophthalmol. 1951;34(12):1675–86.PubMedGoogle Scholar
  11. 11.
    Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513.PubMedGoogle Scholar
  12. 12.
    Thomas TP. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology. 1984;30(1):60–5.PubMedGoogle Scholar
  13. 13.
    Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238(23):787–93.PubMedGoogle Scholar
  14. 14.
    Wong VG, Hersh EM. Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol. 1965;69:279–93.Google Scholar
  15. 15.
    Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98.e1.PubMedCentralPubMedGoogle Scholar
  16. 16.
    Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108(6):1134–9.PubMedGoogle Scholar
  17. 17.
    Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:b2480.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Wakefield D, Abu El-Asrar A, McCluskey P. Treatment of severe inflammatory eye disease in patients of reproductive age and during pregnancy. Ocul Immunol Inflamm. 2012;20(4):277–87.PubMedGoogle Scholar
  19. 19.
    McCluskey P, Chang JH, Singh R, Wakefield D. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology. 2004;111(4):796–801.PubMedGoogle Scholar
  20. 20.
    Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985;312(13):818–22.PubMedGoogle Scholar
  21. 21.
    Wong VG, Hersh EM, McMaster PR. Treatment of a presumed case of sympathetic ophthalmia with methotrexate. Arch Ophthalmol. 1966;76(1):66–76.PubMedGoogle Scholar
  22. 22.
    Kondo Y, Fukuda K, Suzuki K, Nishida T. Chronic noninfectious uveitis associated with Vogt-Koyanagi-Harada disease treated with low-dose weekly systemic methotrexate. Jpn J Ophthalmol. 2012;56(1):104–6.PubMedGoogle Scholar
  23. 23.
    Malik AR, Pavesio C. The use of low dose methotrexate in children with chronic anterior and intermediate uveitis. Br J Ophthalmol. 2005;89(7):806–8.PubMedCentralPubMedGoogle Scholar
  24. 24.
    Dev S, McCallum RM, Jaffe GJ. Methotrexate treatment for sarcoid-associated panuveitis. Ophthalmology. 1999;106(1):111–8.PubMedGoogle Scholar
  25. 25.
    Rothova A, Ossewaarde-van Norel A, Los LI, Berendschot TT. Efficacy of low-dose methotrexate treatment in birdshot chorioretinopathy. Retina. 2011;31(6):1150–5.PubMedGoogle Scholar
  26. 26.
    Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology. 2005;112(6):1066–71.PubMedGoogle Scholar
  27. 27.
    Maust HA, Foroozan R, Sergott RC, et al. Use of methotrexate in sarcoid-associated optic neuropathy. Ophthalmology. 2003;110(3):559–63.PubMedGoogle Scholar
  28. 28.
    Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol. 2001;85(10):1220–4.PubMedCentralPubMedGoogle Scholar
  29. 29.
    Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992;99(9):1419–23.PubMedGoogle Scholar
  30. 30.
    Holz FG, Krastel H, Breitbart A, et al. Low-dose methotrexate treatment in noninfectious uveitis resistant to corticosteroids. Ger J Ophthalmol. 1992;1(3–4):142–4.PubMedGoogle Scholar
  31. 31.
    Kaplan-Messas A, Barkana Y, Avni I, Neumann R. Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm. 2003;11(2):131–9.PubMedGoogle Scholar
  32. 32.
    Soheilian M, Aletaha M, Yazdani S, et al. Management of pediatric Vogt-Koyanagi- Harada (VKH)-associated panuveitis. Ocul Immunol Inflamm. 2006;14(2):91–8.PubMedGoogle Scholar
  33. 33.
    Bom S, Zamiri P, Lightman S. Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm. 2001;9(1):35–40.PubMedGoogle Scholar
  34. 34.
    Baker KB, Spurrier NJ, Watkins AS, et al. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br J Ophthalmol. 2006;90(12):1481–5.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Munoz-Fernandez S, Garcia-Aparicio AM, Hidalgo MV, et al. Methotrexate: an option for preventing the recurrence of acute anterior uveitis. Eye (Lond). 2009;23(5):1130–3.Google Scholar
  36. 36.
    Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32(2):362–5.PubMedGoogle Scholar
  37. 37.
    Giannini EH, Cassidy JT. Methotrexate in juvenile rheumatoid arthritis. Do the benefits outweigh the risks? Drug Saf. 1993;9(5):325–39.PubMedGoogle Scholar
  38. 38.
    Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr. 1998;133(2):266–8.PubMedGoogle Scholar
  39. 39.
    Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med. 1992;326(16):1043–9.PubMedGoogle Scholar
  40. 40.
    Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–96.e3.PubMedGoogle Scholar
  41. 41.
    de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol. 1999;83(4):448–51.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Bae JH, Lee SC. Effect of intravitreal methotrexate and aqueous humor cytokine levels in refractory retinal vasculitis in Behcet disease. Retina. 2012;32(7):1395–402.PubMedGoogle Scholar
  43. 43.
    Taylor SR, Habot-Wilner Z, Pacheco P, Lightman S. Intravitreal methotrexate in uveitis. Ophthalmology. 2012;119(4):878–9.PubMedGoogle Scholar
  44. 44.
    Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology. 2009;116(4):797–801.PubMedGoogle Scholar
  45. 45.
    Taylor SR, Banker A, Schlaen A, et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina. 2013;33(10):2149–54.PubMedGoogle Scholar
  46. 46.
    Rootman J, Gudauskas G. Treatment of ocular leukemia with local chemotherapy. Cancer Treat Rep. 1985;69(1):119–22.PubMedGoogle Scholar
  47. 47.
    Fargher EA, Tricker K, Newman W, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther. 2007;32(2):187–95.PubMedGoogle Scholar
  48. 48.
    Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–9.e2.PubMedCentralPubMedGoogle Scholar
  49. 49.
    Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV. Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm. 2008;16(4):161–5.PubMedGoogle Scholar
  50. 50.
    Moore CE. Sympathetic ophthalmitis treated with azathioprine. Br J Ophthalmol. 1968;52(9):688–90.PubMedCentralPubMedGoogle Scholar
  51. 51.
    Kim SJ, Yu HG. The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2007;15(5):381–7.PubMedGoogle Scholar
  52. 52.
    Mathews JD, Crawford BA, Bignell JL, Mackay IR. Azathioprine in active chronic iridocyclitis. A double-blind controlled trial. Br J Ophthalmol. 1969;53(5):327–30.PubMedCentralPubMedGoogle Scholar
  53. 53.
    Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet’s syndrome. N Engl J Med. 1990;322(5):281–5.PubMedGoogle Scholar
  54. 54.
    Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769–74.PubMedGoogle Scholar
  55. 55.
    Saadoun D, Wechsler B, Terrada C, et al. Azathioprine in severe uveitis of Behcet’s disease. Arthritis Care Res (Hoboken). 2010;62(12):1733–8.Google Scholar
  56. 56.
    Goebel JC, Roesel M, Heinz C, et al. Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol. 2011;95(2):209–13.PubMedGoogle Scholar
  57. 57.
    Hoang-Xaun T, Foster CS, Rice BA. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology. 1990;97(7):892–8.PubMedGoogle Scholar
  58. 58.
    Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527–663.PubMedCentralPubMedGoogle Scholar
  59. 59.
    Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye (Lond). 1998;12(Pt 5):783–8.Google Scholar
  60. 60.
    Vianna RN, Ozdal PC, Deschenes J, Burnier Jr MN. Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. Can J Ophthalmol. 2006;41(2):183–9.PubMedGoogle Scholar
  61. 61.
    Hooper PL, Kaplan HJ. Triple agent immunosuppression in serpiginous choroiditis. Ophthalmology. 1991;98(6):944–51; discussion 51–2.PubMedGoogle Scholar
  62. 62.
    Newell FW, Krill AE. Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc U K. 1967;87:499–511.PubMedGoogle Scholar
  63. 63.
    Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol. 1978;96(2):247–51.PubMedGoogle Scholar
  64. 64.
    Jones EL, Epinette WW, Hackney VC, et al. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol. 1975;65(6):537–42.PubMedGoogle Scholar
  65. 65.
    Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999;106(2):370–4.PubMedGoogle Scholar
  66. 66.
    Klisovic DD. Mycophenolate mofetil use in the treatment of noninfectious uveitis. Dev Ophthalmol. 2012;51:57–62.PubMedGoogle Scholar
  67. 67.
    Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–32. e1-2.PubMedCentralPubMedGoogle Scholar
  68. 68.
    Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation. 2008;86(10):1474–8.PubMedGoogle Scholar
  69. 69.
    Sen HN, Suhler EB, Al-Khatib SQ, et al. Mycophenolate mofetil for the treatment of scleritis. Ophthalmology. 2003;110(9):1750–5.PubMedGoogle Scholar
  70. 70.
    Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115(8):1416–21, 1421.e1.PubMedGoogle Scholar
  71. 71.
    Kolomeyer AM, Ragam A, Shah K, et al. Mycophenolate mofetil in the treatment of chronic non-infectious, non-necrotizing scleritis. Ocul Immunol Inflamm. 2012;20(2):113–8.PubMedGoogle Scholar
  72. 72.
    Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007;91(2):180–4.PubMedCentralPubMedGoogle Scholar
  73. 73.
    Nottage JM, Hammersmith KM, Murchison AP, et al. Treatment of mucous membrane pemphigoid with mycophenolate mofetil. Cornea. 2013;32(6):810–5.PubMedGoogle Scholar
  74. 74.
    Doycheva D, Deuter C, Blumenstock G, et al. Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid. Ocul Immunol Inflamm. 2011;19(6):431–8.PubMedGoogle Scholar
  75. 75.
    Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005;112(8):1472–7.PubMedGoogle Scholar
  76. 76.
    Choudhary A, Harding SP, Bucknall RC, Pearce IA. Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease. J Ocul Pharmacol Ther. 2006;22(3):168–75.PubMedGoogle Scholar
  77. 77.
    Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 1998;352(9121):35–6.PubMedGoogle Scholar
  78. 78.
    Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. 2003;110(5):1061–5.PubMedGoogle Scholar
  79. 79.
    Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol. 2003;31(6):487–91.PubMedGoogle Scholar
  80. 80.
    Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115(10):1826–32.PubMedGoogle Scholar
  81. 81.
    Teoh SC, Hogan AC, Dick AD, Lee RW. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol. 2008;146(5):752–60, 760.e1–3.PubMedGoogle Scholar
  82. 82.
    Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999;159(21):2542–50.PubMedGoogle Scholar
  83. 83.
    Leflunomide approved for rheumatoid arthritis; other drugs nearing approval. Am J Health Syst Pharm. 1998;55(21):2225–6.Google Scholar
  84. 84.
    Baughman RP, Lower EE. Leflunomide for chronic sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2004;21(1):43–8.PubMedGoogle Scholar
  85. 85.
    Roy M. Early clinical experience with leflunomide in uveitis. Can J Ophthalmol. 2007;42(4):634.PubMedGoogle Scholar
  86. 86.
    Molina C, Modesto C, Martin-Begue N, Arnal C. Leflunomide, a valid and safe drug for the treatment of chronic anterior uveitis associated with juvenile idiopathic arthritis. Clin Rheumatol. 2013;32(11):1673–5.PubMedGoogle Scholar
  87. 87.
    Marino A, Wason WM. Successful treatment of idiopathic orbital inflammatory disease with leflunomide: a case report. South Med J. 2009;102(10):1085–7.PubMedGoogle Scholar
  88. 88.
    Teschner S, Burst V. Leflunomide: a drug with a potential beyond rheumatology. Immunotherapy. 2010;2(5):637–50.PubMedGoogle Scholar
  89. 89.
    Robertson SM, Lang LS. Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions. 1994;42(3–4):167–72.PubMedGoogle Scholar
  90. 90.
    Fang CB, Zhou DX, Zhan SX, et al. Amelioration of experimental autoimmune uveitis by leflunomide in Lewis rats. PLoS One. 2013;8(4), e62071.PubMedCentralPubMedGoogle Scholar
  91. 91.
    Niederkorn JY, Lang LS, Ross J, et al. Promotion of corneal allograft survival with leflunomide. Invest Ophthalmol Vis Sci. 1994;35(10):3783–5.PubMedGoogle Scholar
  92. 92.
    Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983;96(3):275–82.PubMedGoogle Scholar
  93. 93.
    Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs. 1993;45(6):953–1040.PubMedGoogle Scholar
  94. 94.
    Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576–84.PubMedCentralPubMedGoogle Scholar
  95. 95.
    Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl. 2002:121–30.Google Scholar
  96. 96.
    Al-Khader AA, Basri N, Al G, et al. Pregnancies in renal transplant recipients--with a focus on babies. Ann Transplant. 2004;9(3):65–7.PubMedGoogle Scholar
  97. 97.
    Perales-Puchalt A, Vila Vives JM, Lopez Montes J, et al. Pregnancy outcomes after kidney transplantation-immunosuppressive therapy comparison. J Matern Fetal Neonatal Med. 2012;25(8):1363–6.PubMedGoogle Scholar
  98. 98.
    Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm. 2005;13(5):335–51.PubMedGoogle Scholar
  99. 99.
    Palestine AG, Nussenblatt RB, Gelato M. Therapy for human autoimmune uveitis with low-dose cyclosporine plus bromocriptine. Transplant Proc. 1988;20(3 Suppl 4):131–5.PubMedGoogle Scholar
  100. 100.
    Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet. 1989;1(8647):1093–6.PubMedGoogle Scholar
  101. 101.
    Nussenblatt RB, Palestine AG, Chan CC, et al. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am J Ophthalmol. 1991;112(2):138–46.PubMedGoogle Scholar
  102. 102.
    Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol. 1985;1(4):369–82.PubMedGoogle Scholar
  103. 103.
    Towler HM, Cliffe AM, Whiting PH, Forrester JV. Low dose cyclosporin A therapy in chronic posterior uveitis. Eye (Lond). 1989;3(Pt 3):282–7.Google Scholar
  104. 104.
    Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996;103(3):365–73; discussion 73–4.PubMedGoogle Scholar
  105. 105.
    Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol. 2010;58(1):55–8.PubMedCentralPubMedGoogle Scholar
  106. 106.
    Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology. 1998;105(11):2028–34.PubMedGoogle Scholar
  107. 107.
    Salzmann J, Lightman S. The potential of newer immunomodulating drugs in the treatment of uveitis: a review. BioDrugs. 2000;13(6):397–408.PubMedGoogle Scholar
  108. 108.
    Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993;115(6):763–9.PubMedGoogle Scholar
  109. 109.
    Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol. 2001;12(2):368–73.PubMedGoogle Scholar
  110. 110.
    Textor SC, Wiesner R, Wilson DJ, et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation. 1993;55(6):1332–9.PubMedGoogle Scholar
  111. 111.
    Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123(5):634–41.PubMedGoogle Scholar
  112. 112.
    Okada AA. Noninfectious uveitis: a scarcity of randomized clinical trials. Arch Ophthalmol. 2005;123(5):682–3.PubMedGoogle Scholar
  113. 113.
    Kainz A, Harabacz I, Cowlrick IS, et al. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int. 2000;13 Suppl 1:S299–300.PubMedGoogle Scholar
  114. 114.
    Armenti VT, Moritz MJ, Davison JM. Breastfeeding and tacrolimus: is it a reasonable approach? Expert Rev Clin Immunol. 2013;9(7):623–6.PubMedGoogle Scholar
  115. 115.
    Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol. 1994;118(6):723–9.PubMedGoogle Scholar
  116. 116.
    Lee RW, Greenwood R, Taylor H, et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology. 2012;119(6):1223–30.PubMedGoogle Scholar
  117. 117.
    Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106(4):723–8.PubMedGoogle Scholar
  118. 118.
    Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114(5):1000–6.PubMedGoogle Scholar
  119. 119.
    Roda-Perez E. Sobre un case se uveitis de etiologia ignota tratado con mostaza introgenada. Rev Clin Esp. 1951;41:265–7.PubMedGoogle Scholar
  120. 120.
    Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117(2):356–65.PubMedCentralPubMedGoogle Scholar
  121. 121.
    Rosenbaum JT. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol. 1994;21(1):123–5.PubMedGoogle Scholar
  122. 122.
    Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology. 2004;111(5):960–5.PubMedGoogle Scholar
  123. 123.
    Suelves AM, Arcinue CA, Gonzalez-Martin JM, et al. Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease. Ophthalmology. 2013;120(6):1201–9.PubMedGoogle Scholar
  124. 124.
    Khan IJ, Barry RJ, Amissah-Arthur KN, et al. Ten-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory disease. Br J Ophthalmol. 2013;97(9):1118–22.PubMedGoogle Scholar
  125. 125.
    Saw VP, Dart JK, Rauz S, et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology. 2008;115(2):253–61.e1.PubMedGoogle Scholar
  126. 126.
    Thorne JE, Woreta FA, Jabs DA, Anhalt GJ. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology. 2008;115(12):2146–52.e1.PubMedGoogle Scholar
  127. 127.
    Mamo JG, Azzam SA. Treatment of Behcet’s disease with chlorambucil. Arch Ophthalmol. 1970;84(4):446–50.PubMedGoogle Scholar
  128. 128.
    Kazmers IS, Daddona PE, Dalke AP, Kelley WN. Effect of immunosuppressive agents on human T and B lymphoblasts. Biochem Pharmacol. 1983;32(5):805–10.PubMedGoogle Scholar
  129. 129.
    Tessler HH, Jennings T. High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet’s disease. Br J Ophthalmol. 1990;74(6):353–7.PubMedCentralPubMedGoogle Scholar
  130. 130.
    Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol. 2008;146(6):802–12.e1.PubMedCentralPubMedGoogle Scholar
  131. 131.
    Durrani K, Zakka FR, Ahmed M, et al. Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease. Surv Ophthalmol. 2011;56(6):474–510.PubMedGoogle Scholar
  132. 132.
    Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behcet’s disease. Ocul Immunol Inflamm. 2001;9(4):219–29.PubMedGoogle Scholar
  133. 133.
    Miserocchi E, Baltatzis S, Ekong A, et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology. 2002;109(1):137–42.PubMedGoogle Scholar
  134. 134.
    Goldstein DA, Fontanilla FA, Kaul S, et al. Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology. 2002;109(2):370–7.PubMedGoogle Scholar
  135. 135.
    Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011;118(10):1916–26.PubMedCentralPubMedGoogle Scholar
  136. 136.
    Sugar EA, Holbrook JT, Kempen JH, et al. Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. Ophthalmology. 2014;121(10):1855–62.PubMedCentralPubMedGoogle Scholar
  137. 137.
    Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect. 2012;2(1):21–8.PubMedCentralPubMedGoogle Scholar
  138. 138.
    Kempen JH CWN, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Stephen Foster C, JabsDA, Levy-Clarke GA, Joffe MM. Methotrexate vs. mycophenolate mofetil for ocular inflammatory diseases. ARVO/Fort Lauderdale Convention Center; 2012.Google Scholar
  139. 139.
    Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121(10):1863–70.PubMedCentralPubMedGoogle Scholar
  140. 140.
    Cervantes-Castaneda RA, Gonzalez-Gonzalez LA, Cordero-Coma M, et al. Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12-month follow-up. Br J Ophthalmol. 2013;97(5):637–43.PubMedGoogle Scholar
  141. 141.
    Tappeiner C, Roesel M, Heinz C, et al. Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye (Lond). 2009;23(5):1192–8.Google Scholar
  142. 142.
    Fresko I, Yazici H. Treatment strategies for Behcet’s disease. Expert Opin Pharmacother. 2008;9(18):3211–9.PubMedGoogle Scholar
  143. 143.
    Agarwal M, Ganesh SK, Biswas J. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome. Ocul Immunol Inflamm. 2006;14(6):333–9.PubMedGoogle Scholar
  144. 144.
    Nguyen QD, Hatef E, Kayen B, et al. A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology. 2011;118(1):184–90.PubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Department of OphthalmologySomdech Phra Pinkloa HospitalBangkokThailand
  2. 2.Department of OphthalmologyChulalongkorn UniversityBangkokThailand
  3. 3.Ophthalmic EpidemiologyProfessor of Ophthalmology, Professor of Epidemiology in Biostatistics and Epidemiology, The Scheie Eye InstitutePhiladelphiaUSA
  4. 4.Department of OphthalmologyCenter for Preventive Ophthalmology and BiostatisticsPhiladelphiaUSA
  5. 5.Department of Biostatistics and EpidemiologyThe Center for Clinical Epidemiology and Biostatistics, The Perelman School of Medicine, University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations